BioCryst to Present at TD Cowen Health Care Conference
Event summary
- BioCryst Pharmaceuticals will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 a.m. ET.
- The presentation will be available via live audio webcast and replay on BioCryst’s website.
- BioCryst focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
- The company has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor.
The big picture
BioCryst’s presentation at the TD Cowen Health Care Conference comes at a time when the biotech sector is under scrutiny for pipeline advancements and commercialization strategies. The company’s focus on rare diseases positions it in a niche market with high unmet medical needs, but it must demonstrate sustained execution to maintain investor confidence. The scale of BioCryst’s commercial success with ORLADEYO® will be a key indicator of its future growth potential.
What we're watching
- Pipeline Progress
- How BioCryst’s advancements in its pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics will impact its market position.
- Market Reception
- Whether the investor community will view BioCryst’s strategic updates favorably, particularly in light of its focus on rare diseases.
- Commercial Success
- The pace at which BioCryst can sustain and grow the commercial success of ORLADEYO® in the competitive HAE treatment landscape.
Related topics